Topic description and stories

Vial of the AstraZeneca COVID-19 vaccine

Incidence of heart attacks and strokes was lower after COVID-19 vaccination

31 Jul 2024

The incidence of heart attacks and strokes was lower after COVID-19 vaccination than before or without vaccination, according to a new study...

Read more
Syringe and vaccine bottle

New vaccine effective against coronaviruses that haven’t even emerged yet

06 May 2024

Researchers have developed a new vaccine technology that has been shown in mice to provide protection against a broad range of coronaviruses with...

Read more
Illustration of mRNA strand

Researchers redesign future mRNA therapeutics to prevent potentially harmful immune responses

06 Dec 2023

Researchers have discovered that misreading of therapeutic mRNAs by the cell’s decoding machinery can cause an unintended immune response in the body...

Read more
Digital generated image of different variants of virus cells against a black background.

New vaccine technology could protect from future viruses and variants

25 Sep 2023

Studies of a ‘future-proof’ vaccine candidate have shown that just one antigen can be modified to provide a broadly protective immune response in...

Read more
Vaccine being administered by needle-free injection into a volunteer's arm

Cambridge University’s needle-free coronavirus vaccine begins clinical trials in home city

24 Apr 2023

Recruitment is underway in Cambridge for volunteers to take part in clinical trials of a revolutionary new needle-free vaccine to protect against...

Read more
Model of coronavirus and hypodermic needle

Referrals to long COVID clinic fell by 79% following roll-out of the vaccine

06 Oct 2022

Referrals to Cambridge’s long COVID clinic fell dramatically in the period August 2021 to June 2022, which researchers say is likely due to the...

Read more
Professor Jonathan Heeney

Cambridge vaccine expert in $42million partnership to develop 'future-proofed' coronavirus vaccines

08 Mar 2022

Prime Minister Boris Johnson announced that DIOSynVax, a biotech spinout of the University of Cambridge, will receive $42 million (about £32 million...

Read more
Covid-19 seen under the microscope. SARS-CoV-2, 3D rendering

Omicron may be significantly better at evading vaccine-induced immunity, but less likely to cause severe disease

20 Dec 2021

The Omicron variant of SARS-CoV-2 may be significantly better than previous variants at evading vaccine-induced antibodies, according to new research...

Read more

Cambridge COVID vaccine in clinical trials

14 Dec 2021

Safety trials are underway for a vaccine developed by Cambridge researchers that could be used as a booster targeting COVID-19 virus variants and...

Read more
UK Emergency Medical Team paediatric nurse checks a girl for symptoms of Diphtheria in the Kutapalong refugee camp, Bangladesh

Diphtheria risks becoming ‘major global threat’ again as it evolves resistance to antimicrobials

08 Mar 2021

Diphtheria – a relatively easily-preventable infection – is evolving to become resistant to a number of classes of antibiotics and in future could...

Read more
Coronavirus

Single dose of Pfizer BioNTech vaccine reduces asymptomatic infections and potential for SARS-CoV-2 transmission

26 Feb 2021

New data from Addenbrooke's Hospital in Cambridge suggests that a single dose of the Pfizer BioNTech vaccine can reduce by 75% the number of...

Read more
Syringe and vaccine

Pfizer BioNTech vaccine likely to be effective against B1.1.7 strain of SARS-CoV-2

02 Feb 2021

The Pfizer BioNTech vaccine BNT162b2 is likely to be effective against the B1.1.7 variant of SARS-CoV-2, even though its efficacy is modestly...

Read more

Pages